- NCIt
- C7711
Loading cancer entity…
Loading cancer entity…
Clinical trials
67 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (11)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00844168 | Sorafenib Tosylate in Treating Patients With Liver Cancer Who Have Undergone a Liver Transplant | completed | Phase 1 | 4 | University of WashingtonOTHER | 1 | Mar 27, 2015 | clinicaltrials |
| NCT02070419 | TACE With or Without Radiation Therapy in Treating Patients With Stage A-C Liver Cancer | withdrawn | Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 0 | Dec 2, 2014 | clinicaltrials |
| NCT00083226 |
| Doxorubicin and Bortezomib in Treating Patients With Liver Cancer |
| completed |
| Phase 2 |
| 42 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Oct 30, 2014 |
| clinicaltrials |
| NCT00604721 | Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | May 28, 2014 | clinicaltrials |
| NCT00639509 | IMC-A12 in Treating Patients With Advanced Liver Cancer | completed | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
| NCT00023946 | BMS-247550 in Treating Patients With Liver or Gallbladder Cancer | terminated | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | May 14, 2014 | clinicaltrials |
| NCT00052364 | Oxaliplatin in Treating Patients With Liver Cancer | completed | Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Jun 18, 2013 | clinicaltrials |
| NCT00238394 | Cediranib Maleate in Treating Patients With Locally Advanced or Metastatic Liver Cancer | completed | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00033462 | Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer | completed | Phase 2 | 78 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00077441 | Bortezomib in Treating Patients With Hepatocellular Carcinoma (Liver Cancer) | completed | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00071994 | Gefitinib in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer) | completed | Phase 2 | 59 | National Cancer Institute (NCI)NIH | 1 | Feb 27, 2013 | clinicaltrials |
| NCT00028496 | Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer | completed | Phase 1 | 48 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00047333 | Erlotinib in Treating Patients With Liver Cancer That Cannot be Surgically Removed | terminated | Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00047346 | Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver Dysfunction | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00030498 | Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction | completed | Phase 1 | 75 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT01194206 | Stereotactic Body Radiation Therapy in Liver Cancer That Cannot be Removed by Surgery or Transplant | withdrawn | Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 0 | Apr 18, 2012 | clinicaltrials |
Data updated 22 days agoSource updated Mar 27, 2015source: clinicaltrials